BIOMAT Database Logo BIOMAT Database Logo

Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients. 1990

N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
Division of Haematology, Hospital for Sick Children, Toronto, Ontario, Canada.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077543 Deferiprone A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA. 1,2-Dimethyl-3-hydroxy-4-pyridinone,1,2-Dimethyl-3-hydroxypyrid-4-one,1,2-Dimethyl-3-hydroxypyridin-4-one,3-Hydroxy-1,2-dimethyl-4-pyridinone,DMOHPO,Ferriprox,HDMPP,1,2 Dimethyl 3 hydroxy 4 pyridinone,1,2 Dimethyl 3 hydroxypyrid 4 one,1,2 Dimethyl 3 hydroxypyridin 4 one,3 Hydroxy 1,2 dimethyl 4 pyridinone
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013789 Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. Thalassemias
D065227 Transfusion Reaction Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility. Delayed Hemolytic Transfusion Reaction,Acute Hemolytic Transfusion Reaction,Blood Transfusion-Associated Adverse Reactions,Delayed Serologic Transfusion Reaction,Febrile Non-Hemolytic Transfusion Reaction,Hemolytic Transfusion Reaction,Hypotensive Transfusion Reaction,Post-Transfusion Purpura,Posttransfusion Purpura,TAGHD,Transfusion-Associated Allergic Reaction,Transfusion-Associated Circulatory Overload,Transfusion-Associated Dyspnea,Transfusion-Associated Graft Vs. Host Disease,Transfusion-Transmitted Infection,Allergic Reaction, Transfusion-Associated,Blood Transfusion Associated Adverse Reactions,Circulatory Overload, Transfusion-Associated,Circulatory Overloads, Transfusion-Associated,Dyspnea, Transfusion-Associated,Febrile Non Hemolytic Transfusion Reaction,Hemolytic Transfusion Reactions,Infection, Transfusion-Transmitted,Post Transfusion Purpura,Posttransfusion Purpuras,Purpura, Post-Transfusion,Purpura, Posttransfusion,Reaction, Hemolytic Transfusion,Reaction, Hypotensive Transfusion,Reactions, Hemolytic Transfusion,Transfusion Associated Allergic Reaction,Transfusion Associated Circulatory Overload,Transfusion Associated Dyspnea,Transfusion Associated Graft Vs. Host Disease,Transfusion Reaction, Hemolytic,Transfusion Reaction, Hypotensive,Transfusion Reactions,Transfusion Reactions, Hemolytic,Transfusion Reactions, Hypotensive,Transfusion Transmitted Infection,Transfusion-Associated Circulatory Overloads,Transfusion-Transmitted Infections

Related Publications

N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
[Long-term treatment of patients with transfusion hemosiderosis using oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1)].
November 1991, Nederlands tijdschrift voor geneeskunde,
N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.
October 1990, British journal of haematology,
N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
September 1990, Clinical pharmacology and therapeutics,
N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
August 1992, Blood,
N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
October 1990, British journal of haematology,
N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
July 1994, Journal of clinical pathology,
N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
December 1987, British medical journal (Clinical research ed.),
N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
April 1987, Journal of clinical pathology,
N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
Methodological issues in studying the effect of the new oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) on absorption of iron.
April 1990, Veterinary and human toxicology,
N F Olivieri, and D M Templeton, and G Koren, and D Chung, and C Hermann, and M H Freedman, and R A McClelland
L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.
December 1990, British journal of haematology,
Copied contents to your clipboard!